Web Analytics

3 Latest Announced Rounds

  • $10,000,000
    Unknown

    3 Investors

    Computer & Network Security
    Apr 24th, 2025
  • $3,000,000
    Seed

    2 Investors

    Medical Equipment Manufacturing
    Apr 24th, 2025
  • $3,000,000
    Seed
    Software Development
    Apr 24th, 2025
$2,018.11M Raised in 62 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Synthetic Design Lab

start up
United States - San Francisco Bay Area
  • 24/04/2025
  • Unknown
  • $20,000,000

A next-generation ADC company developing a novel SYNTHBODY therapeutic platform against a range of cancer types


Related People

Daniel Chen, M.D. Ph.D.Founder

Daniel Chen, M.D. Ph.D. United States - Burlingame, California

Author of The Cancer-Immunity Cycle (Immunity 2013) and the Cancer-Immune Set Point (Nature 2017) with Ira Mellman.

A pioneer in the field of Cancer Immunotherapy, emergence of PD-L1/PD-1 inhibitors and next generation therapies. Focused on the future of medicine and what's possible at the intersection between engineering, science and medicine.

Experienced drug developer (from pre-clinical through Phase I-IV), entrepreneur, executive- strong communicator and strategic leader with expertise in Oncology, Immunology, Large Molecule Engineering, Virology, Filings, Biomarkers and Building/Leading Organizations.